Healthcare Industry Insights: October 2021

Monday 25 October 2021

Blood Ketone Meter Market Size, Share, Analysis and Forecast to 2028

The global Blood Ketone Meter Market size is expected to reach USD 501.5 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.7% from 2021 to 2028. Reimbursement scenario and favorable health insurance are significant factors that are anticipated to surge the demand for blood ketone meters. Technological advancements in Type 1 Diabetes care lead to the increasing preference for automated devices among individuals that aid in reducing disease burden.

Diabetes prevalence is increasing worldwide, due to which the number of hospital admissions with patients suffering from complications, including diabetic ketoacidosis (DKA), is also rising. DKA is a severe and life-threatening complication of diabetes. This disease is more common among people with type 1 diabetes and affects around 30 million people across the U.S. Lifestyle changes, rapid urbanization, increased life expectancy, and dietary changes are the major causes of diabetes.

The rise in the geriatric and obese population across the globe is expected to boost the growth of the market. As per the WHO, by 2050, the world’s population aged 60 years and above is likely to reach 2 billion by 2050. Similarly, as per the American Diabetes Association, one-third of U.S. adults aged 65 and above had diabetes in 2017. Thus, a rise in the number of adults with diabetes is anticipated to boost the demand for blood ketone meters during the forecast period.

An increasing number of hospital admissions owing to the rising cases of DKA in developing as well as developed nations are estimated to foster the market growth. According to a Diabetes Care Study, DKA causes approximately 200,000 hospitalizations each year in the U.S. Rising hospital admissions eventually lead to an increase in healthcare costs, thereby fueling the market growth.

Related Press Release@ Blood Ketone Meter Market Report

Blood Ketone Meter Market Report Highlights

By product type, the blood glucose and ketone monitoring segment held the second-largest share in 2020 due to the increasing launch of blood glucose and ketone meters
Based on application, the veterinary segment is expected to witness considerable growth during the forecast period due to the increasing application of blood ketone meters among animals
The hospital end-use segment captured the largest share in 2020 due to the increasing number of hospitalizations every year
North America held the largest market share in 2020 due to the rising healthcare expenditure and increase in the healthcare spending
The presence of local and international players and the increasing prevalence of type 1 and type 2 diabetes has led to the surging demand for blood ketone meters in North America

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Dental Caries Detectors Market: Key Companies & Market Share Insights

The global Dental Caries Detectors Market size is expected to reach USD 512.0 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.9% from 2021 to 2028. Dental caries detection devices assist in evaluating enamel structure for conditions like caries or micro-fractures in the tooth before sealant placement. Caries detection devices assist in the primary detection of dental caries, which might lead to early diagnosis by the dental professional. Factors like the increasing prevalence of caries, increasing awareness about oral health, and rising advancement in dental diagnostic are expected to propel the market growth.

Dental caries is the most prevalent and preventable dental condition, which if identified early, can be treated by non-invasive techniques. According to the WHO, as of 2017, around 2.3 billion people suffer from caries of permanent teeth and more than 530 million children suffer from caries of primary teeth. Changing lifestyle, high sugar consumption, and less awareness about oral hygiene in low- and middle-income countries are the most common causes for the prevalence of caries.

Moreover, technological advancement in caries detection devices that assures high accuracy and sensitivity for diagnosing caries lesions is expected to propel market growth. For instance, Digital Imaging Fiber Optic Trans-illumination technique has an accuracy of 90% and the images can be stored digitally by the professionals, assisting in providing quality treatment to the patient.

In the light of COVID-19, the global market was hampered as the footfall of patient appointments for surgical treatments was temporarily suspended. However, since the governments in many countries have allowed resuming elective surgical procedures, clinics have also started orthodontic procedures again by adhering to strict Covid-19 protocols. Moreover, many dentists believe that there will be a surge in oral care and dental treatments post-Covid-19 crisis and this is expected to propel the market growth.

Related Press Release@ Dental Caries Detectors Market Report

Dental Caries Detectors Market Report Highlights

Based on product, laser fluorescent caries detector held the largest market share in 2020 as it is the most opted method owing to its ability to diagnose occlusal caries lesions in permanent teeth and enamel and dentin caries
By end-use, dental clinics held the largest share in 2020 as they are readily adopting an advanced diagnostic system to treat dental caries
North America dominated the global market in 2020 owing to the increasing demand for new technologies, a large pool of key players, rising prevalence of dental disorders, and advanced healthcare infrastructure
Asia Pacific is expected to register the highest CAGR over the forecast period due to the rising prevalence of dental caries and the presence of key players

Clinical Trial Kits Market - Future Trends, Revenue Growth & Leading Players, Forecast To 2028

The global Clinical Trial Kits Market size is anticipated to reach USD 2.5 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.5% from 2021 to 2028. The factors driving market expansion include globalization of clinical trials, increasing demand for remote services, and rising clinical trial complexity.

Remote clinical trial services are becoming increasingly essential in terms of patient retention, satisfaction, and safety. To enhance their capabilities, pharmaceutical companies have created a relationship with global logistics partners to provide direct-to-patient services. These services provide participants with the flexibility and convenience of participating in the trials while remaining at home.

COVID-19 pandemic has affected the market which resulted in slowing down the trial process. The COVID-19 pandemic is rapidly boosting advances in medical practices that allow people to connect with the healthcare system remotely. This effort of examining the patients at their homes has raised interest in at-home sample collection and testing. Such services offer convenience and minimize potential exposure to SARS-CoV-2.

Companies began to move to provide direct-to-consumer testing digital services. More aspects of the testing process, from test ordering to sample collection, are already making their way into patients' homes. Besides, regulatory authorities have instantly given sponsors guidelines to resolve issues that have arisen during ongoing clinical studies. Changes such as the use of telemedicine, the elimination of non-essential visits and laboratory assessments, as well as diagnostic testing and sample collection, have allowed many studies to continue while ensuring patient safety during the pandemic.

Related Press Release@ Clinical Trial Kits Market Report

Clinical Trial Kits Market Report Highlights

The logistics segment dominated the market and accounted for the largest revenue share of 54.9% in 2020. This is due to the increasing demand for services to simplify the logistics process in clinical trials
The phase III segment dominated the market and accounted for the largest revenue share of 53.4% in 2020 as phase III trials require a large number of participants
North America dominated the market in 2020 owing to favorable government support and the existence of a large number of companies offering innovative services in the U.S.
In Asia Pacific, the market is projected to witness the highest CAGR of 9.9% over the forecast period as the region is continuously growing in terms of clinical trials due to the vast population and developing technology

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Opportunities and Challenges

The global In-Vitro Toxicology Assays Market size for cannabis and nicotine testing is expected to reach USD 2.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.2% from 2021 to 2028. Growing adoption of high throughput techniques in cannabis testing, legalization of medical cannabis, and growing awareness regarding the potential hazards of nicotine consumption have majorly driven the market throughout the forecast period.

The legalization of medical cannabis is underway globally, including in countries such as Germany, Australia, and Israel. The market is gaining momentum in the Asia Pacific region, with Thailand having fully legalized medicinal cannabis. Thus, increasing legalization of medical cannabis is expected to drive the market growth to a major extend. In addition, technological advancements in cellular assays have boosted the market growth.

COVID-19 has become a catalyst for changing the traditional use of cannabis. Owing to the pandemic, the leading scientific community and market competitors are now focusing on deciphering the potential of cannabis to prevent SARS-CoV-2 infection. Companies have reported the increase in the sale of cannabis as some states/countries have declared cannabis as an essential medicine during the pandemic.

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Report Highlights

Nicotine testing accounted for the largest revenue in 2020 and is expected to continue the trend in the forecast period owing to increasing safety concerns associated with nicotine products
Cannabis testing is expected to witness gradual growth through 2021-2028 owing to the rising acceptance of cannabis for medical use
3D cell culture technology is expected to grow at substantial CAGR owing to the increasing popularity of drug development and toxicity testing
Cytotoxicity testing designing accounted for the highest market revenue in 2020 owing to advancements in different tools for evaluating the cytotoxic effects of nicotine-containing products
North America has emerged as the highest revenue-generating region in 2020, owing to the prevalence of cancer, presence of key players, and developed healthcare infrastructure
Asia Pacific is anticipated to witness the fastest CAGR throughout the forecast period. It is anticipated that China and India are contributing majorly to the regional market’s growth
Key players are undertaking various strategic initiatives such as mergers and acquisitions to maintain their presence in the market
In August 2020, Eurofins Scientific purchased approximately 136 smaller labs within 3 years from 2014 to 2019, accounting for a total expenditure of USD 3.4 billion in these acquisitions

Friday 22 October 2021

Investigational New Drug CDMO Market Size, Share, Analysis and Forecast to 2028

The global Investigational New Drug CDMO Market size is expected to reach USD 6.8 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.9% from 2021 to 2028. This is largely due to the increased R&D investments, along with stringent regulations pertaining to IND.

The U.S. FDA and the European Medicines Agency (EMA) are health authority bodies that regulate the use of investigational drugs in the U.S. and the European Union, respectively. In addition, investigational review boards (IRBs) in the U.S. and ethics committees (ECs) in the European Union must approve the use of drugs in humans.

It is the requirement of a federal law that a drug be the subject of an approved marketing application prior to it is distributed or transported across the state lines. Hence, sponsors aiming to conduct clinical studies that involve an IND should gain exemption from the FDA to permit the shipping of the investigational drug to clinical investigators in several states.

The pandemic has significantly impacted the global economy in 2020 and has an ongoing impact on various industries. However, the market for IND CDMO has benefited from the pandemic. Prior to COVID-19, prospective sponsors demanded facility audits to ensure CDMOs had the required capacity, equipment, and personnel to undertake their projects. Nowadays, CDMOs should find new ways to attract new sponsors, such as through videos, virtual reality, and other technologies that allow sponsors to virtually experience the site.

Related Press Release@ Investigational New Drug CDMO Market Report

Investigational New Drug CDMO Market Report Highlights

In terms of product, the small molecule segment dominated the market with a revenue share of 89.0% in 2020. This is largely due to the increasing number of small molecules in development. Besides, in 2019, the small molecules dominated the new drug approvals accounting for 79% of all the NME approvals
Based on service, the contract development segment led the market with a revenue share of 85.5% in 2020. The contract development offers several benefits over in-house development of drugs, such as access to industry experts, less time to market, cost-effectiveness, and more focus on core competencies
By end user, pharmaceutical companies accounted for the largest share of 69.4% in 2020. This is due to the changes in the pharmaceutical industry that have an impact on research and development strategies, which, in turn, influence new drug approval trends
Asia Pacific to register the fastest growth rate of 7.7% over the forecast period. Due to the rapid growth of pharmaceutical firms and contract manufacturing organizations in developing countries, such as India and China, the region is likely to overtake Europe and North America in the near future

Wednesday 20 October 2021

Asia Pacific Cell Therapy Market: Future Demand, Market Analysis & Outlook to 2028

The Asia Pacific Cell Therapy Market size is expected to reach USD 2.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.9% from 2021 to 2028. Rapid advancements in regenerative medicine are anticipated to provide effective solutions for chronic conditions. A substantial number of companies in the growing markets, such as India and South Korea, are striving to capitalize on the untapped opportunities in the market, thereby driving the market.

The growth is greatly benefitted by the fund and regulatory support from government bodies and regulatory agencies. For instance, in August 2020, the government of South Korea passed an Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine to establish a regulatory system for patient safety during quality control and clinical trials, and to strengthen the regulatory support for regenerative medicine development.

The implementation of the act is expected to enhance clinical studies and approvals of regenerative medicine in South Korea. Furthermore, CAR-T and TCR T-cell therapies have already revolutionized hematologic cancer treatment. With the onset of the COVID-19 pandemic, scientists are deciphering its potential against the novel coronavirus. The concept of using T cells against chronic viral infections, such as HIV and hepatitis B, has already been proposed.

Based on the previous research insights, Singapore-based Duke-NUS medical school’s emerging infectious diseases research program demonstrated the utility of these immunotherapies in treating patients with COVID-19 infection. Thus, an increase in research for use of cell therapies for COVID-19 treatment is expected to drive the market in Asian countries. In April 2021, a team of researchers from Japan used induced pluripotent stem cells (iPS) to find drugs that can effectively inhibit the coronavirus and other RNA viruses.

Related Press Release@ Asia Pacific Cell Therapy Market Report

Asia Pacific Cell Therapy Market Report Highlights

The research-use segment accounted for the major revenue share in 2020. This can to a substantial investment in research and their clinical translation in Asian countries
The segment is also driven by the rapid advances in stem cell research which exhibits the potential to effectively address the unmet demand of pharmaceutical and biotech entities, as well as healthcare professionals in disease management
On the other hand, the clinical use segment is expected to register a significant growth rate during the forecast period owing to the success of CAR-T and other cellular therapies in recent times
Furthermore, the declining price of stem cell therapy products is anticipated to boost sales in this segment coupled with rising demand for effective alternatives to conventional therapies against various chronic indications
Based on the therapeutic area, malignancies captured the maximum revenue share in 2020
This can be owed to relatively more application of cellular therapies in the management of various cancer types such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma
The autologous therapies segment dominated the 2020 market owing to the approval of autologous CAR-T therapies, improved survival rate post transplantation procedures, and relatively higher adoption rate
Japan has emerged as the leading Asian market, which can be attributed to its fast growth as a hub for research on regenerative medicine
On the other hand, Singapore and India are anticipated to witness the fastest growth over the forecast period owing to the presence of improving financing programs to support and advance cell therapy product development in the countries

List of Key Players of Asia Pacific Cell Therapy Market

· Kolon TissueGene, Inc.

· JCR Pharmaceuticals Co., Ltd.

· Kolon TissueGene, Inc.

· JCR Pharmaceuticals Co., Ltd.

· MEDIPOST

· PHARMICELL Co., Ltd.

· ANTEROGEN. CO., LTD

· Bristol-Myers Squibb Company

· Novartis AG

· Gilead Sciences, Inc.

· Curocell, Inc.

· JW Therapeutics (Shanghai) Co., Ltd.

· Stempeutics Research PVT LTD

About Us:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Monday 18 October 2021

Cancer Biopsy Market by Qiagen N.V., Illumina, Inc., ANGLE Plc, BD (Becton, Dickinson And Company)

The global Cancer Biopsy Market size is expected to reach USD 44.51 billion by 2027, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 11.13% from 2021 to 2027. The expanding landscape of molecular medicine paved the way for the development of new devices for the molecular characterization of cancers. Thus, increasing adoption and product approvals for liquid biopsies are expected to drive the overall market.

The kits and consumables product segment is expected to maintain its lead in the years to come. Acknowledging this trend, various market players have invested in the development of novel kits in order to expand their biopsy kits portfolio. For instance, in April 2021, Sysmex Europe GmbH, along with Sysmex Inostics GmbH, introduced Plasma-SeqSensei liquid biopsy research use only (RUO) kits in EMEA.

The tissue biopsies segment emerged as the dominant type segment in 2020. Shortcomings of liquid biopsies such as the lack of robust efficacy evaluations and associated high costs are currently bridged by tissue biopsies. This has made tissue biopsy a gold-standard procedure in the present diagnostic scenario.

Liquid biopsies are expected to offer lucrative opportunities in the field of oncology-based personalized medicine and genomic data analysis. Recognizing the potential of these tests, the regulatory bodies are actively supporting the commercialization of these products and increasing the use of these assays in clinics. For instance, in November 2020, the FoundationOne Liquid CDx test was approved by the U.S. FDA as a companion diagnostic device for multiple cancers.

The liquid biopsies segment is expected to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by companies involved in biopharmaceutical manufacturing and genomic data analysis are expected to play a central role. The emerging companies are inclined towards collaborating with well-established industry participants, including SOPHiA Genetics, QIAGEN Bioinformatics, Agilent Technologies, and Fabric Genomics. This trend is further expected to favor the overall market growth.

Key players are focusing on developing novel biopsy platforms, set to achieve business expansion, further contributing to the revenue generation in the market. In March 2021, Quick-Core Auto Biopsy System for biopsy procedure soft tissue biopsy was launched by IZI Medical Products. This product is fully automated, which is built based on the company’s proprietary semi-automatic system, Quick-Core.

Related Press Release@ Cancer Biopsy Market Report

Cancer Biopsy Market Report Highlights

By product, kits and consumables accounted for the largest revenue share in 2020 and are anticipated to maintain its lead throughout the forecast period. The adoption of kits and consumables is expected to increase owing to the significant transition from tumor to liquid biopsy
Based on type, tissue biopsies are still considered to be a mainstay of biopsies and are largely adopted across various diagnosis applications. Additionally, tumor biopsy is most adopted for diagnosis on individual levels, along with monitoring the effects of an ongoing oncology treatment
North America held the largest revenue share in 2020 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity
In terms of application, breast cancer dominated the global market in 2020 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy is considered to be a reference standard for the evaluation of patients with a suspicious breast lesion. This is attributed to its proven accuracy in diagnosing breast lesions, further contributing to the revenue generated by this segment

List of Key Players of Cancer Biopsy Market

· Qiagen N.V.

· Illumina, Inc.

· ANGLE Plc

· BD (Becton, Dickinson And Company)

· Myriad Genetics

· Hologic, Inc.

· Biocept, Inc.

· Thermo Fisher Scientific, Inc.

· Danaher

· F. Hoffmann-La Roche Ltd.

· Lucence Diagnostics Pte. Ltd.

· GRAIL, Inc.

· Guardant Health

· Exact Sciences Corporation

· Freenome Holdings, Inc.

· Biodesix (Integrated Diagnostics)

· Oncimmune

· Epigenomics AG

· HelioHealth (Laboratory for Advanced Medicine)

· Genesystems, Inc. (Genesys Biolabs)

· Chronix Biomedical, Inc.

· Personal Genome Diagnostics Inc.

· Natera, Inc.

· Personalis Inc.

About Us: